Iohexol, platelet activation and thrombosis
|
|
- Ellen George
- 5 years ago
- Views:
Transcription
1 Acta Radiologica ISSN: (Print) (Online) Journal homepage: Iohexol, platelet activation and thrombosis Kjell S. Sakariassen, M. Buchmann, M. J. A. G. Hamers & H. Stormorken To cite this article: Kjell S. Sakariassen, M. Buchmann, M. J. A. G. Hamers & H. Stormorken (1998) Iohexol, platelet activation and thrombosis, Acta Radiologica, 39:4, To link to this article: Published online: 04 Jan Submit your article to this journal Article views: 43 Full Terms & Conditions of access and use can be found at
2 Acta Radiologica 39 (1998) Prinred in Denmark - AN rights reserved Copyright 0 Acra Radiologicu 1998 AC TA R A D 1 0 L 0 G I CA ISSN IOHEXOL, PLATELET ACTIVATION AND THROMBOSIS 11. Iohexol-induced platelet secretion does not affect collageninduced or tissue-factor-induced thrombus formation in blood that is anticoagulated with heparin and aspirin K. S. SAKARIASSEN"~, M. BUCHMANN', M. J. A. G. HAMERS' and H. STORMORKEN' 'Nycomed Imaging AS, Bioreg Research, Oslo; and 'Department of Biology, Division of General Physiology, University of Oslo, Oslo; Norway. Abstract Background: There is a dispute about the potential effects of radiographic contrast media (CM) on thrombogenesis. The nonionic CM iohexol triggers platelet P-thromboglobulin (P-TG) secretion, and thus may activate the platelets and promote thrombosis. We addressed this topic in a study employing a human model of arterial thrombus formation in the presence of aspirin and heparin. This was a follow-up to our initial study (on thrombus formation in native blood) which did not include antithrombotic drugs. The nonionic CM iohexol (monomer) and iodixanol (dimer) and the ionic CM ioxaglate (dimer) were compared. Methods and Results: Thrombus formation was triggered by a surface rich in either collagen or tissue factor, positioned in a parallel-plate perfusion chamber device at an arterial wall shear rate of 2600 s-i. Blood from healthy volunteers, following ingestion of 1 g aspirin, was mixed with 40 vol% CM and 2.0 IU/ml heparin and passed over the surfaces. Thrombus formation in the presence of either CM showed no difference, despite the fact that iohexol triggered a pronounced platelet p-tg secretion; iodixanol or ioxaglate were virtually inert. Conclusion: There was no association between iohexol-induced P-TG secretion and thrombus formation on collagen (platelet-driven) or on tissue factor (thrombin-driven) in the presence of a standard antithrombotic regimen of aspirin and heparin as used in the clinic. The notion of a thrombotic risk due to platelet activation by iohexol was thus not substantiated by this study. Key words: Contrast media, iohexol, iodixanol, ioxaglate; platelet activation; thrombus formation; arterial shear. Correspondence: Kjell S. Sakariassen, Department of Biology, Division of General Physiology, PO. Box 1051, Blindern, N Oslo, Norway. FAX t Accepted for publication 10 December Ionic and nonionic contrast media (CM) inhibit in vitro blood plasma coagulation and blood platelet aggregation in plasma with a high platelet level. It is generally accepted that ionic CM are stronger inhibitors than nonionic CM (2, 24). These differences would appear to be of no significance in vivo in the presence of proper antithrombotic drug administration since the incidence of thrombo-embolic disorders reported for the two types of CM does not differ in procedures of angiography (1, 22) or percutaneous transluminal coronary angioplasty (PTCA) (6, 9). However, recent reports have indicated a slightly increased incidence of thrombosis following the use of the nonionic CM iohexol in PTCA (3, 5), particularly in patients with acute ischemic syndromes (7). Quite reasonably, the discussion has included the in vitro observation that P-thromboglobulin (p- TG) secretion is induced by the nonionic CM iohexol but not by the ionic CM ioxaglate (1). 355
3 K. S. SAKARIASSEN ET AL. Since P-TG is generally used as a specific marker for intravascular platelet activation and thromboembolism (lo), the question naturally arose as to whether iohexol is a platelet activator and as such a prothrombotic. Such a possibility seems remote since iohexol inhibits in vitro platelet aggregation and is therefore by definition no platelet agonist but rather a weak platelet antagonist (24). Indeed, the collagen-induced thrombus formation in native human blood mixed with iohexol in a well characterized thrombus-forming device at arterial shear (20) was no different from the thrombus formed in blood mixed with the ionic ioxaglate or nonionic iodixanol(l9). This hding was observed in spite of the high iohexol-elicited P-TG secretion; ioxaglate or iodixanol did not trigger significant P- TG secretion. Nevertheless, the potential consequences of the iohexol-dependent P-TG secretion for thrombus formation in flowing anticoagulated blood are unknown and demand attention. This prompted us to study the potential effects of iohexol-dependent P-TG secretion on arterial thrombus formation in blood that is anticoagulated with clinically relevant doses of aspirin and heparin. For this purpose, we employed a parallelplate perfusion chamber device in which thrombus formation is triggered by purified human type I11 collagen fibrils or by human tissue factor/phospholipids at high arterial shear (13, 19, 20). Under these experimental conditions, the collagen-induced thrombus formation is independent of coagulation whereas the tissue-factor-induced coagulation is thrombin-driven (4, 12). In this way, the potential effects of CM on collagen-dependent or thrombin-dependent thrombus formation were differentiated and quantified at clinically relevant doses of aspirin and heparin. Also of importance was the fact that previous experience with this model and these thrombus-promoting surfaces had demonstrated an association between the size of the platelet thrombus and the P-TG plasma levels (12-16), e.g. large thrombi resulted in higher P-TG plasma levels than smaller thrombi did. However, our recently performed study on the effect of CM or glucose in native human blood (19) showed no such parallel - on the contrary, thrombus formation at increasing glucose osmolality showed the opposite association: the platelet thrombus volume decreased in parallel with increasing P-TG secretion. Material and Methods Contrast media and controls: The following CM were used: iohexol (Omnipaque, nonionic monomer, 350 mg I/ml, 825 mosmol, Nycomed Amers- ham); iodixanol (Visipaque, nonionic dimer, 320 mg I/ml, 280 mosmol, Nycomed Amersham); and ioxaglate (Hexabrix, ionic dimer, 320 mg Uml, 580 mosmol, Guerbet). A glucose solution of 300 mosmol was used as control. Blood donors: Twenty healthy young nonsmoking men donated (with informed consent) 110 ml blood for two perfusion experiments on the same day. The blood parameters hematocrit, hemoglobin, platelet count, and leukocyte count were within the normal ranges for all donors. All volunteers ingested 1 g aspirin (Novid, Nycomed Pharma) two hours before the first of the two successive perfusions. This aspirin dose completely blocks the formation of the platelet thromboxane A2 by its irreversible acetylation of the cyclo-oxygenase (1 8). In one perfusion, the blood was used to study the potential effects of one of the three CM on thrombus formation. In the other perfusion, the blood was used for the glucose control. Of the first perfusions, half were performed with CM and the other half with glucose. Thrombogenic surfaces: The surfaces used to trigger thrombus formation consisted either of type I11 collagen fibrils purified from human placenta (4, 19, 20) or of a tissue-factor/phospholipid preparation made from human placenta (Thrombore1 S, Behringwerke AS, Marburg, Germany) (12, 13). These preparations have previously been characterized biochemically and used in studies of thrombus formation in flowing native or anticoagulated human blood (4, 12-16, 19, 20). Human ex vivo thrombosis model and perfusions: The parallel-plate perfusion chamber device (20, 21) connected with the mixing device was employed (12, 19). In this system, native blood is drawn directly by an occlusive roller pump from an antecubital vein over the collagen-coated or the tissue-factor/phospholipid-coated cover slip surface positioned in the flow channel of the perfusion chamber. The pump is placed distal to the perfusion chamber. The mixing device, which is positioned proximal to the perfusion chamber, homogeneously mixed CM, unfractionated heparin (Heparin, 5000 IU/ml, Nycomed Pharma) or glucose when pumped into the ex vivo blood stream from the vein. Thus, the introduction of a solution into the blood flow results in homogeneous mixing of solution and blood proximal to the perfusion chamber and the thrombus-promoting surface. All blood-contact surfaces of the mixing device (Carmeda AB, Stockholm, Sweden) were covalently coated with heparin to minimize the activation of platelets and coagulation (12). Blood perfusions with CM or glucose lasted for 5 min at an arterial wall shear rate of 2600 s-*. 356
4 IOHEXOL, PLATELET ACTIVATION AND THROMBOSIS - I1 This shear rate is within the range of those encountered in vessels with moderate atherosclerosis (25). The flow rate was 10 ml/min. In all the perfusion experiments, the CM or glucose in the blood was 40 ~01%. Heparin was infused together with CM or glucose at a ha1 concentration in the diluted blood of 2.0 IU/ml. For the termination of blood perfusion, specimen fixation and epoxy resin embedding, we used the same procedures as described in our previous report (19). Measurement of plasma p-tg: Plasma levels of P-TG (IU/ml) from blood samples drawn distal to the perfusion chamber at 4 min of perfusion (14, 19) were quantified by radio-immunometric assay (Amersham, UK). The upper level of the normal range of plasma P-TG was defined as 40 IU/ml. Thrombus morphometry was performed on 1- pm-thick epoxy-embedded sections as previously described (19, 21). Thrombus parameters for fibrin deposition (% of surface coverage with fibrin), platelet adhesion (YO of surface coverage with platelets), and platelet thrombus volume (pm3/pm2 thrombus volume) were measured. Coagulation assay: Activated partial thromboplastin time was measured with the Cephotest (Nycomed Pharma). Statistical analysis: The results are expressed as mean2sem or mean+sd. Significance for the paired and nonpaired data was calculated by means of the Student's two-tailed t-test. Values of p<0.05 were considered significant B r T N Results Heparin anticoagulation: Heparin introduction into the ex vivo blood stream prolonged the activated partial clotting time from to s (meanksd, n=4). Collagen-induced thrombus formation: Fibrin deposition in presence of CM or the 300 mosmol glucose control covered less than 1% of the surface. Platelet-collagen adhesion (Fig. 1A) did not differ with the various CM or glucose used. The platelet thrombus volume (Fig. 1B) was within the same range, irrespective of the CM used. The average thrombus volume was lower in blood mixed with glucose. The only significant statistical difference (P<O.OOl) in thrombus volume was observed in blood mixed with glucose. Iohexol profoundly increased the P-TG plasma level (P<O.OOl) (Fig. 1C). In contrast, the P-TG plasma levels in blood mixed with iodixanol or ioxaglate were low and within the same range as in the glucose control. Tissue-factor-induced thrombus formation: None " iodlxand glucose iohexol ioxaglate Fig. 1. Thrombus formation elicited by fibrillar collagen in blood containing aspirin and heparin in the presence of CM at a wall shear rate of 2600 s-i. A) Platelet-collagen adhesion (X of surface coverage with platelets). B) Platelet thrombus volume (pm3/pm2). C) P-TG plasma levels (IWml). Mean-CSEM, n=5. Student's t-test *** p<o.ool. 357
5 K. S. SAKARIASSEN ET AL. 201 c B = E \ D T a k cp. E d 1000 h iodixanol glucose lodlxanol glucose iohexol loxaglate iohexol loxaglate Fig. 2. Thrombus formation elicited by tissue-factor in blood containing aspirin and heparin in the presence of CM at a wall shear rate of 2600 s-*. A) Fibrin deposition (% of surface coverage with fibrin). B) Platelet-fibrin adhesion ( 3% of surface coverage with platelets). C) Platelet thrombus volume (pm3/pm2). D) P-TG plasma levels (IU/ml). Mean? SEM, n=5. Student s t-test *** p<o.ool. of the CM affected fibrin deposition (Fig. 2A). The fibrin deposition was within the same range as that observed in blood mixed with glucose. Platelet-fibrin adhesion (Fig. 2B) was not affected by the CM. The adhesion level was within the same range as that in the presence of glucose. The platelet thrombus volume (Fig. 2C) did not differ according to the presence of the various CM. The average thrombus volume was lower in blood mixed with glucose, although not significantly different from those in blood mixed with CM. Representative light-micrographs of tissue-factor-induced thrombi on semi-thin sections were prepared perpendicular to the direction of the blood flow (Fig. 3). Thrombi formed in the presence of the various CM showed no apparent differences in morphology or size (Fig. 3). However, the average thrombus size in the presence of glucose appeared lower than those in the presence of CM (Fig. 3D). The plasma levels of P-TG (Fig. 2D) reached much higher values in the presence of iohexol than in the presence of iodixanol, ioxaglate or glucose (p<o.ool). Discussion Thrombo-embolic events during and shortly after PTCA procedures are much feared. In this regard, the activation of platelets by angiography CM has been a central issue. We have addressed this issue in studies employing a human model of thrombus formation that was previously used to assess the relationship between platelet P-TG secretion and thrombus formation in human blood with or with- 358
6 IOHEXOL, PLATELET ACTIVATION AND THROMBOSIS ~ I1 Fig. 3. Representative light micrographs of tissue-factor-induced thrombi formed in the presence of CM, aspirin and heparin following 5-min perfusions at a wall shear rate of 2600 s-l. The semi-thin sections were prepared perpendicular to the direction of the blood flow. A) Thrombus formed in the presence of 40 vol% iohexol. B) Thrombus formed in the presence of 40 vol% ioxaglate. C) Thrombus formed in the presence of 40 vol% iodixanol. D) Thrombus formed in the presence of 40 vol% 300 mosmol glucose. No differences in thrombus morphology or size were observed in the presence of CM. However, inclusion of glucose reduced the thrombus volume, although not statistically significant. Magnification X 800. out the presence of various platelet antagonists (14-16). In these experiments, it was shown that a significant decrease in thrombus formation resulted from the oral administration of aspirin, clopidogrel or a reversible thromboxane A2 receptor antagonist and was reflected in a concomitant decrease in the plasma levels of P-TG. However, our recent experiments with CM, native blood and this perfusion chamber device demonstrated that this association was not always present since the profound iohexol-induced p-tg secretion was not associated with an enhanced thrombus formation (19). Furthermore, an increasing glucose osmolality which increased the p-tg secretion was paralleled by a decreasing thrombus formation (19). In this current study, we have extended our previous investigation on iohexol-induced P-TG secretion and thrombus formation (19). We employed the same ex vivo thrombosis model at the same high arterial shear, plus two vascular surfaces where thrombus formation is platelet-driven (collagen) or thrombin-driven (tissue factor), and blood that was anticoagulated with clinically relevant doses of aspirin and heparin. No evidence of enhanced thrombus formation elicited by iohexol was observed, despite the fact that iohexol triggered a pronounced secretion of P-TG. Average thrombus volumes in blood mixed with ioxaglate or iodixanol were no different from that elicited by iohexol, although the first two CM did not induce significant P-TG secretion. Thus, the P-TG secretion and the size of the platelet thrombi did not parallel each other as previously observed in a number of studies with platelet antagonists in the same model (14-16). However, the current data accord well with our recently reported findings on iohexol-induced P-TG secretion and a corresponding nonaffected collagen-induced thrombus formation in native blood (19). The iohexol-induced P- TG secretion is apparently not affected by clinical doses of aspirin and heparin. The collagen-induced thrombus formation did not differ according to the CM investigated. Thrombus formation at this wall shear rate of 2600 s-l is independent of coagulant activity (4, 12) and is thus entirely platelet-driven. In spite of the very high plasma levels of P-TG triggered by iohexol, this platelet-dependent thrombus formation was not enhanced. This indicates that iohexol is not a true platelet agonist, at least not in this arterial blood flow condition, since the platelet thrombus volume was not significantly affected. Furthermore, it is well known and generally accepted that iohexol is an antagonist of in vitro induced platelet aggregation (24). This assay is performed at relatively low shear conditions (shear rate of <300 s-'). However, the possibility remains open that iohexol renders platelets less responsive
7 K. S. SAKARIASSEN ET AL. to further agonist stimuli, as has been observed upon repeated stimuli by adenosine diphosphate or collagen (8, 17). Alternatively, the secretion of inhibitory platelet substance(s) (such as a plateletderived growth factor which inhibits thrombin-induced in vitro platelet aggregation) (26) may neutralize the apparent iohexol- or glucose-induced platelet activation. Thus, platelet alpha granules possess both prothrombotic and antithrombotic substances which are secreted upon platelet activation. The tissue-factor-dependent coagulation and fibrin deposition were not inhibited by the CM. This is contrary to in vitro coagulation assays in which ioxaglate appears as the strongest inhibitor of the three CM (2, 23, 24). It is possible that the presence of the antithrombotic drugs had already suppressed coagulation and fibrin deposition so that an additional inhibition by CM was not detected by the morphometric approach. Platelet thrombus formation did not differ in the presence of either of these CM, and can thus be seen as analogous to the apparent lack of CM effect on coagulation. It is noted that on this surface with its high level of tissue factor, platelet thrombus formation is entirely dependent on the deposited fibrin mesh (12), and thus on coagulation. Our present study shows that high shear platelet-driven or thrombin-driven platelet thrombus formation does not differ in the presence of iohex- 01, iodixanol or ioxaglate at clinical doses of aspirin and heparin. Thus the use of this model system, with two relevant thrombus-promoting vascular surfaces and with human blood containing a standard antithrombotic drug regimen as used in PTCA, shows that iohexol does not promote thrombus formation despite its apparent platelet activation. Studies are currently being planned on the potential effects of these CM on thrombus formation at a lower shear, which is also present in PTCA-treated vessels. REFERENCES 1. CHRONOS N. A. F., GOODALL A. H., WILSON D. J., SIGWART U. & BULLER N. l?: Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation 88 (1993), ELOY R., COROT C. & BELLEVILLE J.: Contrast media for angiography. Physicochemical properties, pharmacokinetics and biocompatibility. Clin. Mat. 7 (1991), ESPLUGAS E., CEQUIER A,, FRANCISCO J. et al.: Risk of thrombosis during coronary angioplasty with low osmolality contrast media. Am. J. Cardiol. 68 (1991), FRESSINALJD E., SAKARIASSEN K. S., ROTHSCHILD C., BAUMGARTNER H. R. & MEYER D.: Shear rate dependent decrease of thrombus growth on collagen in non-anticoagulated blood from patients suffering from von Willebrand disease or hemophilia A. Blood 80 (1992), GASPERETTI C. M., FELDMAN M. D., BURWELL. R. et al.: Influence of contrast media on thrombus formation during coronary angioplasty. J. Am. Coll. Cardiol. 18 (1991), GERTZ E. W.: Thromboembolic events and non-ionic contrast. Diagn. Imaging 58 (1989), GRINES C. L., SCHREIBER T. L., SAVAS V. et al.: A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J. Am. COIL Cardiol. 27 (1996), HALLAM T. J., RUGGLES P, A., SCRUTTON M. C. & WALLIS R. B.: Desensitisation in human and rabbit platelets. Thromb. Haemost. 47 (1982), JONSON L. W., KRONE R. & THE REGISTRY COMMITTEE OF THE SOCIETY FOR CARDIAC ANGI~GRAPHY AND INTER- VENTION (SCA & I): Cardiac catheterization. Cath. Cardiovasc. Diagn. 28 (1993), KAPLAN K. & OWEN J.: Plasma levels of thromboglobulin and platelet factor 4 as indices of platelet activation in viva Blood 57 (1981), LEVORSTAD K., VATNE K., BRODAHL U., AAKHUS T., B- MONSEN S. & VIK H.: Cerebral thromboembolic cornplications associated with the use of non-ionic contrast medium in coronary angiography. Acta Radiol. 36 (1995), RVIM U., BARSTAD R. M., VLASUK G.F! & SAKARIASSEN K. S.: Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factodfactor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler. Thromb. Vasc. Biol. 15 (1995), ORVIM U., ROALD H. E., STEPHENS R. W., RWs N. & SAKA- RIASSEN K. S.: Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions. Arterioscler. Thromb. 14 (1994), ROALD H. E., BARSTAD R. M., ENGEN A,, KIERULF I?, SKJBRTEN E & SAKARIASSEN K. S.: HN a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb. Haemost. 71 (1994), ROALD H. E., BARSTAD R. M., KIERULF? et al.: Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in human non-anticoagulated blood independently of the blood flow conditions. Thromb. Haemost. 71 (1994), ROALD H. E., ORVIM U., BAKKEN I. J., BARSTAD R. M., KIERUL F! & SAKARIASSEN K. S.: Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. Arterioscler. Thromb. 14 (1994), ROSENBERG M. C. & HOLMSEN H.: Adenine nucleotide metabolism of gel filtered blood platelets. I\! Platelet aggregation responses to ATP and AD! Biochem. Biophys. Acta 157 (1968), ROTH G. J. & MAJERUS F! W.: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest. 56 (1975), SAKARIASSEN K. S., BARSTAD R. M., HAMERS M. J. A. G. & STORMORKEN H.: Iohexol, platelet activation and thrombosis. I. Iohexol-induced platelet secretion does not affect thrombus formation in native blood. Acta Radiol. 39 (1998), SAKARIASSEN K. S., Joss R., MUGGLI R. et al.: Collagen type I11 induced ex vivo thrombogenesis in humans. Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 19 (1990), SAKARIASSEN K. S., MUGGLI R. & BAUMGARTNER H. R.: Measurements of platelet interaction with components of the vessel wall in flowing blood. In: Methods in enzy- 360
8 IOHEXOL, PLATELET ACTIVA TION AND THROMBOSIS - I1 mology, vol. 169, p. 37. Edited by J. Hawiger. Academic Press Inc., New York SKALPE I. 0.: Complications in cerebral-angiography with iohexol (Omnipaque) and meglumine metrizoate (Isopaque cerebral). Neuroradiology 30 (1988), STORMORKEN H. & SAKARIASSEN K. S.: Contrast media effects on hemostatic and thrombotic parameters. Consequences for practial techniques and prophylactic measures. Acta Radio]. (1999, Suppl. 399, p STORMORKEN H., SKALPE I. 0. & TESTART M. C.: Effect of various contrast media on coagulation, fibrinolysis, and platelet function. An in vitro and in vivo study. Invest. Radio]. 21 (1986), TURITTO V. T. & BAUMGARTNER H. R.: Initial deposition of platelets and fibrin on vascular surfaces in flowing blood. In: Hemostasis and thrombosis. Basic principles and clinical practice, vol. 39, p Edited by R. W. Colman et al. J. B. Lippincott Co., Philadelphia VASSBOTN E S., HAVNEN 0. K., HELDIN C.-H. & HOLMSEN H.: Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor alpha receptor. J. Biol. Chem. 269 (1994),
Modulation of Thrombotic Responses in Moderately Stenosed Arteries by Cigarette Smoking and Aspirin Ingestion
617 Modulation of Thrombotic Responses in Moderately Stenosed Arteries by Cigarette Smoking and Aspirin Ingestion Helge E. Roald, Una 0rvim, Inger J. Bakken, R. Marius Barstad, Peter Kierulf, Kjell S.
More informationLa Trombosi Arteriosa
La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They
More informationThe potential merits and disadvantages of ionic versus
Influence of a Nonionic, Iso-Osmolar Contrast Medium () Versus an Ionic, Low-Osmolar Contrast Medium () on Major Adverse Cardiac Events in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationJournal of the American College of Cardiology Vol. 33, No. 2, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 2, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(98)00600-7 A Randomized
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationThrombosis. Jeffrey Jhang, M.D.
Thrombosis Jeffrey Jhang, M.D. Introduction The human hemostatic system has evolved to maintain blood flow under normal physiologic conditions while remaining primed to rapidly respond to vascular injury
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationCHAPTER-I MYOCARDIAL INFARCTION
CHAPTER-I MYOCARDIAL INFARCTION Definition A myocardial infarction, more commonly known as MI or acute myocardial infarction (AMI) or heart attack is a condition where there is interruption of blood supply
More informationOutline Anti-coagulant and anti-thrombotic drugs Haemostasis and Thrombosis Year 3 Dentistry
Outline Anti-coagulant and anti-thrombotic drugs Year 3 Dentistry Professor Yotis Senis Cellular Haemostasis y.senis@bham.ac.uk I. Haemostasis and II. Coagulation and anti-coagulants III. Platelets and
More informationCoronary angioplasty has undergone dramatic evolution. Randomized Trial of Contrast Media Utilization in High-Risk PTCA.
Randomized Trial of Contrast Media Utilization in High-Risk PTCA The COURT Trial Charles J. Davidson, MD; Warren K. Laskey, MD; James B. Hermiller, MD; J. Kevin Harrison, MD; William Matthai, Jr, MD; Ronald
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationChapter 19. Hemostasis
Chapter 19 Hemostasis Hemostasis Hemostasis is the cessation of bleeding stopping potentially fatal leaks important in small blood vessels not effective in hemorrhage excessive bleeding from large blood
More informationLinköping University Post Print. Atrial fibrillation and platelet reactivity
Linköping University Post Print Atrial fibrillation and platelet reactivity Micha Milovanovic, Elisabeth Fransson, Claes Hallert and Petter Järemo N.B.: When citing this work, cite the original article.
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationHemostasis and Thrombosis
Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic
More informationPlatelet glycoprotein IIb/IIIa receptor inhibitors (GPIs) are
Comparative Antithrombotic Effects of Magnesium Sulfate and the Platelet Glycoprotein IIb/IIIa Inhibitors Tirofiban and Eptifibatide in a Canine Model of Stent Thrombosis Vladimir Rukshin, MD; Prediman
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationIMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationAdenosine Diphosphate-induced Platelet Aggregation in the States of Hypercoagulability
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 7, No. 2 Copyright 1977, Institute for Clinical Science Adenosine Diphosphate-induced Platelet Aggregation in the States of Hypercoagulability TEH Y. WANG,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
More informationCHAPTER 17 Antithrombotic Agents Heparins
CHAPTER 17 Antithrombotic Agents Heparins Structure Mechanism of Action Pharmacokinetics Limitations of Unfractionated Heparin Heparin Induced Thrombocytopenia Heparin Rebound Low Molecular Weight Heparins
More informationEffect of an Ionic Compared to a Non-Ionic X-Ray Contrast Agent on Platelets and Coagulation during Diagnostic Cardiac Catheterisation
Pathophysiology of Haemostasis andthrombosis Original Paper Pathophysiol Haemost Thromb 2002;32:121 126 DOI: 10.1159/000065213 Received: April 11, 2002 Accepted in revised form: May 20, 2002 Effect of
More informationHemostasis and Blood Forming Organs
Hemostasis and Blood Forming Organs Subcommittee: Williams, Patricia B. (Chair) pbwillia@umich.edu McMillan, David dcmcmillan@unmc.edu Dobrydneva, Yuliya dobrydy@evms.edu DEFEROXAMINE FERROUS SULFATE ferrous
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationVehicle ACT. 180 min. Time After Current Initiation (min) 180 min. Vehicle. UFH (75 U/kg) Anti-Factor Xa. Time After Current Initiation (min)
Efficacy of, a Rationally-Engineered Low-Molecular-Weight Heparin, in a Canine Model of Arterial Thrombosis Ian D Fier, Mark A Nedelman, J Luis Guerrero, Ganesh Venkataraman, and Yi Wei Qi Momenta Pharmaceuticals,
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationTopics of today lectures: Hemostasis
Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms of hemostasis - Vascular contraction - Platelets plug - Blood coagulation (clotting) - Structure and functions of platelets - Blood
More informationLink between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention Rabah M, Mason D, Muller D W, Hundley R, Kugelmass
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationPlatelet function testing in cardiovascular diseases
Hematology, 2005; 10 Supplement 1: 132 /137 PLATELET DISORDERS Platelet function testing in cardiovascular diseases ALAN D. MICHELSON From the Center for Platelet Function Studies, Departments of Pediatrics,
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationSchematic Of Heparin Induced Thrombocytopenia Platelet Count
Schematic Of Heparin Induced Thrombocytopenia Platelet Count Normal IgG and IgG2 differentially inhibit HIT antibody-dependent platelet activation that platelet counts were lower in FcγRIIA 131RR patients
More informationJournal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationNitroglycerin and Heparin Drip Interfacility Protocols
Nitroglycerin and Heparin Drip Interfacility Protocols EMS Protocol This protocol applies to nitroglycerin and Heparin drips that are initiated at the transferring facility prior to transport and are not
More informationHemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins
Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes
More informationIschaemic heart disease. IInd Chair and Clinic of Cardiology
Ischaemic heart disease IInd Chair and Clinic of Cardiology Definition Syndrome due to chronic insufficient oxygen supply to myocardial cells Nomenclature: ischaemic heart disease (IHD), coronary artery
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationA Case of Contrast-Induced Encephalopathy Using Iodixanol
540 J ENDOVASC THER CASE REPORT A Case of Contrast-Induced Encephalopathy Using Iodixanol Emiliano Chisci, MD, PhD; Francesco Setacci, MD; Gianmarco de Donato, MD; and Carlo Setacci, MD Department of Surgery,
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης Αναπλ. Καθηγητής Καρδιολογίας Ιπποκράτειο ΓΝΑ Haematology Research Laboratory!! Platelets Small anucleate discoid cells Involved
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More information1 Description. 2 Indications. 3 Warnings ASPIRATION CATHETER
Page 1 of 5 ASPIRATION CATHETER Carefully read all instructions prior to use, observe all warnings and precautions noted throughout these instructions. Failure to do so may result in complications. STERILE.
More informationPathophysiology. Tutorial 3 Hemodynamic Disorders
Pathophysiology Tutorial 3 Hemodynamic Disorders ILOs Recall different causes of thrombosis. Explain different types of embolism and their predisposing factors. Differentiate between hemorrhage types.
More informationCurrent Treatment Of Ischemic Heart Disease In the United States: An Overview. By Dr Gary Mo
Current Treatment Of Ischemic Heart Disease In the United States: An Overview By Dr Gary Mo 1 Ischemic Heart Disease in the US 1. Cardiovascular disease remains the most common cause of death and is responsible
More informationCh. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma
Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the
More informationThrombi are composed of fibrin and blood cells and may
AHA Scientific Statement Guide to Anticoagulant Therapy: Heparin A Statement for Healthcare Professionals From the American Heart Association Jack Hirsh, MD; Sonia S. Anand, MD; Jonathan L. Halperin, MD;
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationClinical Investigation and Reports
Clinical Investigation and Reports Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin Sonia S. Anand, MD,
More information4/23/2009. September 15, 2008
The Current Treatment of Deep Venous Thrombosis: Are We Doing Enough? George H. Meier, MD Professor and Chief Division of Vascular Surgery University of Cincinnati College of Medicine Cincinnati, Ohio
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More information12 Lead EKG Chapter 4 Worksheet
Match the following using the word bank. 1. A form of arteriosclerosis in which the thickening and hardening of the vessels walls are caused by an accumulation of fatty deposits in the innermost lining
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationAcquired: Not genetic, produced by influences such as illness, treatment, and lifestyle.
GLOSSARY OF TERMS A Acquired: Not genetic, produced by influences such as illness, treatment, and lifestyle. Activated partial thromboplastin time (aptt): A test to measure inhibition of coagulation, specifically,
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationATHEROSCLEROSIS. Secondary changes are found in other coats of the vessel wall.
ATHEROSCLEROSIS Atherosclerosis Atherosclerosis is a disease process affecting the intima of the aorta and large and medium arteries, taking the form of focal thickening or plaques of fibrous tissue and
More informationComparison of Mean Platelet Volume in Acute Myocardial Infarction vs. Normal Coronary Angiography
Global Journal of Health Science; Vol. 8, No. 11; 2016 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Comparison of Mean Platelet Volume in Acute Myocardial Infarction
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationOUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.
INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra
More informationReprinted in the IVIS website with the permission of the ACVP and ASVCP
Proceedings of the Annual Meeting of the American College of Veterinary Pathologists and American Society for Veterinary Clinical Pathology - Tucson, Arizona 2006 - Reprinted in the IVIS website with the
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationVersion 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM
Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058
More informationWhat hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
More informationCatheter Interventions for Kawasaki Disease: Current Concepts and Future Directions
REVIEW DOI 10.4070/kcj.2011.41.2.53 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright 2011 The Korean Society of Cardiology Open Access Catheter Interventions for Kawasaki Disease: Current Concepts
More informationJournal of the American College of Cardiology Vol. 48, No. 11, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.12.084
More informationEDUCATIONAL COMMENTARY PLATELET DISORDERS
EDUCATIONAL COMMENTARY PLATELET DISORDERS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn
More informationDefining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention
Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention Aggregate Results From 6 Randomized, Controlled Trials Derek P. Chew, MBBS; Deepak L. Bhatt, MD; A. Michael Lincoff,
More informationP-RMS: LT/H/PSUR/0004/001
Core Safety Profile Active substance: Dalteparine Pharmaceutical form(s)/strength: Solution for injection, 2500 I.U./0.2ml, 2500 I.U./ml, 5000 I.U./0.2ml, 7500 I.U./0.3ml, 7500 I.U./0.75ml, 10000 I.U./0.4ml,
More informationUNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.
UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood
More informationCATH LAB SYMPOSIUM 2010
CATH LAB SYMPOSIUM 2010 Low resistance system High Pressure in Capillaries to filter plasma RBF: 1.2-1.3 L/min (25% of C.O.) Low AV difference ( shunt ) Kidney: 14 ml O2/L blood Brain: 62 ml O2/L blood
More informationThrombin injection vs Conventional Surgical Repair in Treatment of Iatrogenic Post-cath Femoral Artery Pseudoaneurysm (IFAP)
Kasr El Aini Journal of Surgery VOL., 11, NO 3 September 2010 31 Thrombin injection vs Conventional Surgical Repair in Treatment of Iatrogenic Post-cath Femoral Artery Pseudoaneurysm (IFAP) Farghaly A,
More informationAntithrombotic therapy in difficult clinical conditions
Antithrombotic therapy in difficult clinical conditions 4 : 5 Pankaj Manoria, PC Manoria, KK Saha, Piyush Manoria, Bhopal Introduction With the development of newer and more potent antithrombotic agents
More informationBIVASTAT Injection (Bivalirudin)
Published on: 1 Aug 2014 BIVASTAT Injection (Bivalirudin) Compostion BIVASTAT Each vial contains: Bivalirudin.. 250 mg Excipients.q.s. Supplied with 5 ml Sterile Water for Injection, IP Dosage Form Sterile
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More information